These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 35552967)

  • 1. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
    Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
    J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Engineered Delivery with the Pharmacokinetics of Medical Candidates via Physiology-Based Pharmacokinetics.
    Yang Y; Zhang X
    Methods Mol Biol; 2022; 2486():57-69. PubMed ID: 35437718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
    Mackie C; Arora S; Seo P; Moody R; Rege B; Pepin X; Heimbach T; Tannergren C; Mitra A; Suarez-Sharp S; Borges LN; Kijima S; Kotzagiorgis E; Malamatari M; Veerasingham S; Polli JE; Rullo G
    Mol Pharm; 2024 May; 21(5):2065-2080. PubMed ID: 38600804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary.
    Tsakalozou E; Mohamed MF; Polak S; Heimbach T
    AAPS J; 2023 Oct; 25(6):96. PubMed ID: 37783902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
    Wu D; Li M
    Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.
    Anand O; Pepin XJH; Kolhatkar V; Seo P
    Pharm Res; 2022 Aug; 39(8):1681-1700. PubMed ID: 35585448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report.
    Mitra A; Suarez-Sharp S; Pepin XJH; Flanagan T; Zhao Y; Kotzagiorgis E; Parrott N; Sharan S; Tistaert C; Heimbach T; Zolnik B; Sjögren E; Wu F; Anand O; Kakar S; Li M; Veerasingham S; Kijima S; Lima Santos GM; Ning B; Raines K; Rullo G; Mandula H; Delvadia P; Dressman J; Dickinson PA; Babiskin A
    J Pharm Sci; 2021 Feb; 110(2):594-609. PubMed ID: 33152375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
    Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
    Guimarães M; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
    Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
    J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
    Le Merdy M; Tan ML; Sun D; Ni Z; Lee SC; Babiskin A; Zhao L
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):41-51. PubMed ID: 33064292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.
    Emami Riedmaier A; Lindley DJ; Hall JA; Castleberry S; Slade RT; Stuart P; Carr RA; Borchardt TB; Bow DAJ; Nijsen M
    J Pharm Sci; 2018 Jan; 107(1):495-502. PubMed ID: 28993217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report.
    Parrott N; Suarez-Sharp S; Kesisoglou F; Pathak SM; Good D; Wagner C; Dallmann A; Mullin J; Patel N; Riedmaier AE; Mitra A; Raines K; Butler J; Kakhi M; Li M; Zhao Y; Tsakalozou E; Flanagan T; Dressman J; Pepin X
    J Pharm Sci; 2021 Feb; 110(2):584-593. PubMed ID: 33058891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.